MTOR and cancer: Results of studies from many centres on a panel of human cancer cell lines of different histological origin confirmed the role of PTEN status in determining pharmacological interactions between RAF/MEK and PI3K/AKT/mTOR pathways inhibitors (Weeber et al. 2017; Sathe et al. 2018; Milella et al. 2017).